SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001157523-23-000411
Filing Date
2023-03-08
Accepted
2023-03-08 16:03:08
Documents
13
Period of Report
2023-03-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 MIRUM PHARMACEUTICALS, INC. 8-K a53358541.htm   iXBRL 8-K 27241
2 EXHIBIT 99.1 a53358541_ex991.htm EX-99.1 126559
  Complete submission text file 0001157523-23-000411.txt   306369

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mirm-20230308.xsd EX-101.SCH 3932
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mirm-20230308_lab.xml EX-101.LAB 23288
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mirm-20230308_pre.xml EX-101.PRE 16556
7 EXTRACTED XBRL INSTANCE DOCUMENT a53358541_htm.xml XML 4390
Mailing Address 950 TOWER LANE, SUITE 1050 FOSTER CITY CA 94404
Business Address 950 TOWER LANE, SUITE 1050 FOSTER CITY CA 94404 650-667-4085
Mirum Pharmaceuticals, Inc. (Filer) CIK: 0001759425 (see all company filings)

IRS No.: 831281555 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38981 | Film No.: 23716116
SIC: 2834 Pharmaceutical Preparations